Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM’s medical microneedling products, the company announces in a news release.
Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch in the United States. The agreement may be expanded with additional products in the future.
The German-engineered Exceed system from MT.DERM, powered by its brand amiea med, is a dual-indicated, FDA-cleared medical microneedling device that is clinically proven to dramatically reduce the appearance of facial wrinkles and facial acne scars. In parallel, it is CE registered in Europe.
Candela manufactures and distributes the Profound system – a real-time, temperature-controlled, long pulse radiofrequency (RF) microneedling device. With the Exceed medical microneedling system, Candela further enhances its existing microneedling portfolio and positions the company for expanded market penetration, the company notes in the release.
“We are delighted to enter into a partnership with MT.DERM, based on their superior engineering and deep understanding of needling technology,” says Geoffrey Crouse, CEO of Candela.
“Microneedling is an essential component of any medical aesthetics practice. The addition of the Exceed medical microneedling system strengthens Candela’s product portfolio, which continues to provide customers the most comprehensive offering of best-in-class medical aesthetic technologies.”
“MT.DERM’s value of quality and engineering excellence, partnered with Candela’s commitment to ‘Science, Results, Trust’ along with their global customer support capability and commercial strength, make this an ideal partnership for us,” adds Joern Kluge, founder and CEO of MT.DERM.
“Candela and MT.DERM jointly have the industry experience and reputation to make the Exceed device a leader in the mechanical microneedling global market.”
[Source(s): Candela, PR Newswire]
